Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
DO Dow Jones Newswires Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co. 7/1/2026, 07:57 PM GMT+8 Dow Jones Newswires AK AKBA Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co. Market News GlobeNewswire Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Reuters Akebia Therapeutics - Voice Trial Meets Stopping Criteria With Win Odds Of 1.16 As Of June 1, 2026 TradingView Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint GlobeNewswire U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
